In a setback for Merck (MRK), a court in London ruled that the big drug maker breached a decades-old agreement with Merck KGgA — an entirely different pharmaceutical company — and infringed on a trademark by using the name “Merck” in the United Kingdom.

The ruling by the High Court of Justice, which follows an appeal of a similar decision four years ago, is the latest twist in a convoluted but heated battle between the two drug makers over their corporate nomenclature.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • What is this and why are both companies making this such a big deal and acrimonious interactions? IMO both companies should be forbidden to use the wordquired Merck alone for any public documents for any purposes and instead required to use Merck KGga and Merck Sharp & dohme. Each time and everybtime!

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy